DR-3355, the S-(-)-isomer of ofloxacin, was generally twice as potent as ofloxacin against a variety of gram-positive and gram-negative pathogens, and its action was bactericidal. The compound was characterized by having the highest level of activity against staphylococci, Bacteroides fragilis, and Peptococcus spp. of the fluorinated quinolones tested, including ofloxacin, ciprofloxacin, fleroxacin, and NY-198. The activity of DR-3355 was not affected by different media, inoculum size, or human serum, but decreased under acidic conditions at pH 5.0 or in human urine.
During the past decade, the development of fluorinated quinolones such as norfloxacin (6) , ofloxacin (10) , ciprofloxacin (12) , fleroxacin (3) , and NY-198 (4) has been aimed mainly at enhancing activity against gram-negative and gram-positive pathogens. Among these compounds, ofloxacin (10) is characterized chemically by a tricyclic structure with a methyl group at the C-3 position in the oxazine ring, thus providing an asymmetric center at this position ( Fig. 1 ). In the course of studies on the structure-activity relationships between stereochemistry and activity, two optically active isomers of ofloxacin, i.e.,
DR-3355 [S-(-)-ofloxacin] and DR-3354 [R-(+)-ofloxacin]
, were prepared successfully by use of their optically resolved synthetic intermediates ( Fig. 1) (2) . A preliminary study of the spectrum of activity of these isomers against selected laboratory strains revealed that DR-3355 was 8 to 128 times more potent than DR-3354 and approximately twice as active as ofloxacin (2) . In this paper we describe the in vitro activity of DR-3355, relative to other fluorinated quinolones, against a large number of clinical isolates.
MATERIALS AND METHODS
Compounds. DR-3355 and ofloxacin were synthesized at the Research Institute, Daiichi Seiyaku Co., Ltd., Tokyo, Japan, as were ciprofloxacin, fleroxacin, and NY-198. Methicillin sodium (Banyu Pharmaceutical Co., Ltd., Tokyo, Japan) and clindamycin phosphate (Japan Upjohn Ltd., Tokyo, Japan) were commercial products.
Organisms 1.56 to 3.13 p.g/ml; its activity was roughly comparable to that of ciprofloxacin and 2 to 8 times higher than those of ofloxacin, fleroxacin, and NY-198. Against various members of the family Enterobacteriaceae, the activity of DR-3355 was equal to or slightly less than that of ciprofloxacin and 2 to 4 times higher than those of ofloxacin, fleroxacin, and NY-198. DR-3355 inhibited most isolates (90%) of Escherichia coli, Klebsiella spp., Proteus spp., Morganella morganii, Providencia spp., Enterobacter spp., Citrobacter freuindii, and Serratia marcescens at 0.05, 3.13, 0.19, 6.25, 3.13, 0.78, 6.25, and 12.5 ,ug/ml, respectively. Glucosenonfermenting gram-negative bacteria, including Pseudomonas aeruginosa, Xanthomonas maltophilia, and Alcaligenes faecalis, were less susceptible to DR-3355 than were members of the family Enterobacteriaceae. Against P. aeruginosa, DR-3355 inhibited 50% and 90% of the isolates at concentrations of 1.56 and 50 ,ug/ml, respectively; its activity was inferior to that of ciprofloxacin but superior to those of ofloxacin, fleroxacin, and NY-198. The activity of DR-3355 against X. maltophilia and A. faecalis was twice as high as those of the reference quinolones tested, with MICs against 50% of isolates (MIC50s) of 1.56 and 3.13 ,uglml, respectively. H. influenzae and N. gonorrhoeae were highly susceptible to DR-3355, which had MIC90s of 0.025 and 0.10 ,ug/ ml, respectively. DR-3355 was more than 2 to 8 times as active as ofloxacin, ciprofloxacin, fleroxacin, and NY-198 against B. fragilis and Peptococcus spp., including those resistant to clindamycin.
Factors affecting the activity. The activity of DR-3355 against S. aureus 209P, E. coli NIHJ, and P. aeruginosa 32104 was the same or varied by one dilution when five different media (Mueller-Hinton, nutrient, brain heart infusion, heart infusion, and tryptose blood agars) were used (data not shown). Varying the pH of Mueller-Hinton agar between 6.0 and 8.0, adding 50% human serum to the medium, or increasing the inoculum size from 103 to 107 and 90% of isolates were killed (MBC50 and MBC90, respectively) of DR-3355 against each species were identical to the M'C50 and MIC90, respectively, indicating that DR-3355 is highly bactericidal. Although data are not shown, both ofloxacin and ciprofloxacin were also verified to be bactericidal. DISCUSSION DR-3355 is an interesting new quinolone with a broad spectrum of activity, and its action was bactericidal. The compound was characterized by its high level of activity against staphylococci and anaerobes, including those resistant to methicillin and clindamycin, respectively; however, it exhibited slightly less activity than ciprofloxacin against gram-negative pathogens, including P. aeruginosa. DR-3355 was generally twice as potent as ofloxacin, and no isolates showed higher susceptibility to ofloxacin than to DR-3355. The difference in activity between these two compounds has been shown to be largely attributed to their anti-DNA gyrase activity (5, 7, 13). Gerster et al. (1) reported that the S-isomer of the tricyclic quinolone analog fused with a piperidine ring was also much more active than the R-isomer and tended to be twice as active as the racemic mixture.
After peroral administration to laboratory animals, DR-3355 was well absorbed, was distributed rapidly to various tissues, and was excreted efficiently in the urine as an unchanged form, and no chiral inversion from DR-3355 to 
